A5021631368- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Intraperitoneal and Appendiceal Malignancies
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Cancer Mechanisms and Therapy
- Cancer, Lipids, and Metabolism
- Neuroendocrine Tumor Research Advances
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Ferroptosis and cancer prognosis
- Cancer, Hypoxia, and Metabolism
- Cancer-related molecular mechanisms research
- Peptidase Inhibition and Analysis
- DNA Repair Mechanisms
- Hepatocellular Carcinoma Treatment and Prognosis
- Epigenetics and DNA Methylation
- Colorectal and Anal Carcinomas
- Lung Cancer Research Studies
- Cancer Research and Treatments
- Ovarian cancer diagnosis and treatment
- Cancer Treatment and Pharmacology
University of Southern California
2017-2025
USC Norris Comprehensive Cancer Center
2018-2024
University of North Carolina at Chapel Hill
2024
Mayo Clinic
2024
Caris Life Sciences (United States)
2023
Istituto Oncologico Veneto
2014-2021
Istituti di Ricovero e Cura a Carattere Scientifico
2015-2020
Keck Hospital of USC
2018
Candiolo Cancer Institute
2018
University of Turin
2018
Tumor screening for Lynch syndrome is recommended in all or most patients with colorectal cancer (CRC). In metastatic CRC, sequencing of RAS/BRAF necessary to guide clinical management. We hypothesized that a next-generation (NGS) panel identifies and other actionable mutations could also reliably identify tumors DNA mismatch repair protein deficiency (MMR-D) on the basis increased mutational load.We identified CRCs underwent genomic mutation profiling custom NGS assay (MSK-IMPACT) between...
Purpose: Even if RAS-BRAF wild-type and HER2/MET-negative metastatic colorectal cancer (mCRC) patients frequently respond to anti-EGFR mAbs, acquired resistance almost invariably occurs. Mechanisms of EGFR blockade include the emergence KRAS, NRAS, extracellular domain mutations as well HER2/MET alterations. However, these findings derive from retrospective studies that analyzed one single mechanism at a time; moreover, it is still unclear how molecular heterogeneity affects clonal evolution...
Right- and left-sided colorectal cancers (CRCs) differ in clinical molecular characteristics. Some retrospective analyses suggested that patients with right-sided tumors derive less benefit from anti-epidermal growth factor receptor (EGFR) antibodies; however, selection those studies was not extensive.Patients RAS BRAF wild-type metastatic CRC (mCRC) who were treated single-agent anti-EGFRs or cetuximab-irinotecan (if refractory to previous irinotecan) included the study. Differences outcome...
IntroductionPrognosis of biliary tract cancers (BTC) remains dismal and novel treatment strategies are needed to improve survival. BRCA mutations known occur in BTC but their frequency the molecular landscape which they observed distinct sites remain unknown.Material methodsTumour samples from 1292 patients with BTC, comprising intrahepatic cholangiocarcinoma (IHC, n=746), extrahepatic (EHC, n=189) gallbladder cancer (GBC, n=353), were analysed using next-generation sequencing (NGS). Tumour...
The natural history and prognosis of appendiceal adenocarcinomas differ from those arising in other large bowel sites. We aimed to compare the molecular profiles exhibited by colorectal cancers, or between histopathologic subtypes adenocarcinoma.A total 183 samples adenocarcinoma [46 adenocarcinoma, not otherwise specified (NOS), 66 pseudomyxoma peritonei (PMP), 44 mucinous (MU), 27 signet ring cell carcinoma (SR)], 994 right-sided cancer (R-CRC), 1,080 left-sided CRC (L-CRC) were analyzed...
Abstract Purpose: GEP-NENs are rare malignancies with increasing incidence. Their molecular characteristics still undefined. We explored the underlying biology of and differences between gastrointestinal (GI) pancreatic (PNEN), high-grade (HG), low-grade (LG) tumors. Experimental Design: were analyzed using next-generation sequencing (NGS; MiSeq on 47 genes, NextSeq 592 genes), IHC, in situ hybridization. Tumor mutational burden (TMB) was calculated basis somatic nonsynonymous missense...
The phase III Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial found no difference in overall survival (OS) patients with metastatic colorectal cancer receiving first-line chemotherapy combination either bevacizumab or cetuximab. We investigated the potential prognostic predictive value of
The identification of new biomarkers and the development novel, targetable contexts vulnerability are urgent clinical need in drug-resistant metastatic colorectal cancer (mCRC). Aryl-Hydrocarbon-Receptor-Nuclear-Translocator-Like (ARNTL/BMAL1) is a circadian clock-regulated transcription factor promoting expression genes involved angiogenesis tumour progression. We hypothesised that BMAL1 increases vascular endothelial growth A VEGFA gene and, thereby, confers resistance to anti-angiogenic...
Defective DNA damage response (DDR) is a hallmark of cancer leading to genomic instability and associated with chemosensitivity. Although the mismatch repair system has been extensively studied, clinical implications other mechanisms DDR alterations in patients colorectal remain unclear. This study aimed understand pathways their association common features cancer.Next-generation sequencing whole-transcriptome were conducted using formalin-fixed paraffin-embedded samples submitted commercial...
Abstract Purpose: Gene fusions involving R-spondin (RSPOfp) and RNF43 mutations have been shown to drive Wnt-dependent tumor initiation in colorectal cancer. Herein, we aimed characterize the molecular features of RSPOfp/RNF43 mutated (mut) compared with wild-type (WT) cancers gain insights into potential rationales for therapeutic strategies. Experimental Design: A discovery cohort was classified status using DNA/RNA sequencing IHC. An independent used validate our findings. Results: The...